Grid Therapeutics Closes A Round from Longview Intl. of Singapore

Grid Therapeutics of Durham, North Carolina completed an A financing of unspecified size to develop its cancer immunotherapy. The lone investor in the round was Longview International of Singapore, a firm that invests in novel life science companies. Last month, Grid acquired global rights to an innovative antibody technology discovered by Duke University researchers, based on targeting a protein that protects tumor cells from the immune system. Grid plans to start a Phase I trial of the candidate in 2019. More details.... Share this with colleagues: // //